Stock AnalizOcular Therapeutix, Inc. OCUL
Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026
Ocular Therapeutix, Inc. (OCUL) is a healthcare company listed in the US with a market value of about $1.4B. In the twelve months to September 30, 2026 it had revenue of $50M and net income of -$327M, a net margin of -648.6%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 24% a year, a 5-year average ROIC of -48%.
Score: 0.8 / 5
Checks passed
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50M | $52M | $64M | $58M | $51M | $44M | $17M | $4M | $2M | $2M | $2M |
| Net income | -$327M | -$266M | -$194M | -$81M | -$71M | -$7M | -$156M | -$86M | -$60M | -$63M | -$45M |
| Free cash flow | -$267M | -$217M | -$136M | -$76M | -$63M | -$67M | -$54M | -$80M | -$51M | -$59M | -$36M |
| EPS (diluted) | $-1.44 | $-1.42 | $-1.22 | $-1.02 | $-0.97 | $-0.98 | $-2.56 | $-1.91 | $-0.42 | $-2.20 | $-1.80 |
| Net margin | -648.6% | -511.9% | -303.7% | -138.1% | -137.9% | -15.1% | -894.3% | -2043.3% | -3014.0% | -3296.2% | -2369.0% |
| ROIC | — | -29.2% | -34.7% | -39.4% | -87.6% | -51.1% | -45.0% | -215.8% | -77.0% | -110.8% | -50.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 11 analysts is $25.73, 314% above the current price; targets range from $14.00 to $34.00; the consensus rating is “Strong buy”; expected EPS is $-1.53 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Ocular Therapeutix pay a dividend?
Not currently.
Is Ocular Therapeutix a good stock to buy?
We do not give buy or sell advice. Ocular Therapeutix scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.